WILMINGTON, Mass., April 16, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today reported that
the Company has received an order for 66 QS-B220 explosives trace
detection systems in Norway. The
systems, many of which have already been shipped, are scheduled to
be deployed for passenger and baggage screening in an airport
environment.
"We estimate that the near-term market for new trace detection
screening programs in aviation security in Europe will exceed $45
million. Implant Sciences' leadership in non-radioactive ion
mobility spectrometry technology has been demonstrated in passing
the ECAC Common Evaluation Protocol on the first try, as well as in
numerous airport trials. We believe our field-proven reliability
and low false alarm rates will lead to even more airports selecting
Implant Sciences as their preferred ETD vendor," stated Dr.
Darryl Jones, Implant Sciences' Vice
President of Global Sales and Marketing.
"One of the primary requirements of this customer was the quick
delivery and installation of non-radioactive ETD systems across the
vast distances and challenging terrain covered by these airports.
Implant Sciences' investment in manufacturing capability made it
possible for us to exceed the customer's expectations in this
area," added Richard Nelson, Implant
Sciences' General Manager, EMEA.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCalâ„¢ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013 Homeland Security Award
for "Best Explosives Detection Solution". All Implant
Sciences products are recognized as Qualified Anti-Terrorism
Technologies by the Department of Homeland Security. For further
details on the Company and its products, please visit the Company's
website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-receives-order-for-66-explosives-trace-detection-systems-in-norway-300067170.html
SOURCE Implant Sciences Corporation